Furthermore, UALCAN analysis showed that Mfn2 was lower in glioblastoma multiforme, sarcoma, and thymoma (Figure 6J), and the higher level of Mfn2 was correlated with poorer OS in patients with sarcoma and thymoma (Figures 6K and 6L). This evidence concerns the gene MFN2 and glioblastoma.